Obesity Medications
4 articles on Obesity Medications, written by Shotlee and medically reviewed for clinical accuracy.
Why Fitness Bros Are Buzzing About Retatrutide Weight-Loss Peptide
Fitness enthusiasts and longevity experts are raving about Retatrutide, the new triple-agonist weight-loss peptide dubbed 'the ultimate good' by influencers. Outshining GLP-1 drugs like Ozempic, it targets three receptors for superior fat reduction. As phase 3 trials advance toward FDA approval, here's why it's generating massive buzz.
6 min read
India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
5 min read
Novo Crash Cuts Wegovy Maker Shareholder Assets by a Third
Novo Nordisk A/S's dramatic stock slump has reduced controlling shareholder Novo Holdings' assets by about a third to 694 billion Danish kroner ($108 billion). Facing cheaper copycats and Eli Lilly rivalry, the Wegovy maker confronts steep sales declines. Despite challenges, the fund posted 9% returns.
5 min read
Big Food Invests Millions in Rebrands as GLP-1 Drugs Reshape Demand
Global food giants like PepsiCo and Coca-Cola are ramping up investments in rebranded, protein-rich products as GLP-1 drugs suppress appetite and alter eating habits across 20% of U.S. households. With potential $12 billion in lost snack sales over the next decade, companies are shifting to smaller portions and nutrient-dense options. This adaptation highlights the lasting ripple effects of obesity medications on the food industry.
5 min read